Bristol-Myers’s Acquisition of ImClone

On July 31, 2008, Bristol-Myers Squibb Company announced that it has proposed to acquire ImClone Systems Incorporated for $60 per share in cash, or a total payment of approximately $4.5 billion, to the equity holders of ImClone (other than Bristol-Myers Squibb). Bristol-Myers Squibb currently owns approximately 17% of all outstanding shares of ImClone, a global leader in the development of novel antibodies to treat cancer. The lawyers involved in this matter are partners Allen Finkelson, Thomas E. Dunn and Susan Webster, associates Mile T. Kurta and Assaf Oz and summer associates Jessica Batzell, Scott S. Bernstein, Frederic Chang and Kevin R. Grondahl on corporate matters; partners Stephen L. Gordon and Lauren Angelilli and associates Ellen Kandel-Burg and Amanda J. Albert on tax matters; partner Eric W. Hilfers, senior attorney Rolf Zaiss and associate M. C. Tania Balthazaar on executive compensation and benefits matters; and senior attorney Gregory J. Battista and associate Annmarie M. Terraciano on environmental matters.